In the subset of patients with tumours lacking TROP2 overexpression (score 0), median overall survival time was 15 months and decreased to 14 months (score 1–4), 10 months (score 5–8) and 7 months (score 9–12) with increasing staining scores. This evidence concerns the gene TACSTD2 and neoplasm.